Created on Saturday, 29 March 2014 11:07
HAVANA, Cuba, Mar 28 (acn) Cuban scientists presented in two forums held in the United States the successful results of the use of the new medicament Heberprot-P for the treatment of complex diabetic foot ulcers, which prevent amputation of lower limbs.
One of them was the technical seminar carried out by the Pan-American Health Organization in Washington, and the other one a meeting at the Conference on the Management of Diabetic Foot Ulcers (DFCON, Los Angeles, 2014), the most important of its kind bringing together U.S. professionals treating patients with this ailment.
Participating in the meetings were Drs. Jorge Berlanga, creator of Heberprot-P, and Boris Acevedo, an official of the Business Department of the Center of Genetic Engineering and Biotechnology (CIGB), which developed the medicament, according to information provided to ACN by the Department of International Relations-Cooperation of that scientific institution.
In the conference, the CIGB experts –of the BioCubaFarma business group- expounded details of the mechanism of action supporting the results obtained in the clinical studies and in the use of the product, which in the world has benefited more than 145,000 patients and with which over 28,000 diabetics have so far been treated in Cuba.
Professionals attending the meetings acknowledged the quality of Heberprot-P and its scientific support, as well as the clinical effects that turn it into an option for the treatment of diabetic foot ulcers.